Microglial uptake and inactivation of epoxyeicosatrienoic acid in stroke injury

描述（由申请人提供）：中风是美国第三大死亡原因和长期残疾的主要原因。大多数急性中风治疗的临床试验都失败了，这表明需要确定新的治疗靶点并开发有效的治疗方法来减少脑损伤。我们在这一建议中的广泛目标是揭示控制神经炎症，特别是小胶质细胞在中风损伤中的有害作用的分子途径。获得的知识将有助于确定中风治疗的新药物靶点。中心假设是小胶质细胞在缺血期间被激活，并有助于损伤的发展。本文探讨了这种小胶质细胞介导的损伤的两个方面：缺血时环氧二碳三烯酸（EET）的消耗增加了神经元的死亡，以及缺血后EET的失活，增加了小胶质细胞的激活，进一步加剧了损伤。在Specific Aim 1中，我们将确定小胶质细胞是否通过cd36介导的摄取消耗EET，以及EET缺乏是否会导致缺血后神经元死亡。在Aim 2中，我们将确定小胶质细胞EET的消耗是否有助于体内中风损伤。在Aim 3中，我们将测试阻断小胶质细胞EET失活是否会减少小胶质细胞的激活和小胶质细胞介导的神经元死亡。最后，在Aim 4中，我们将在体内研究小胶质细胞中抑制eet灭活可溶性环氧化物水解酶是否会阻断脑卒中后小胶质细胞的激活并减轻脑卒中损伤。总体目标是开发和表征中风临床问题的新实验方法，特别是了解小胶质细胞对中风病理的贡献，以及利用对小胶质细胞/神经元相互作用和小胶质细胞介导的损伤的日益了解来确定急性中风的新治疗靶点和方法。该实验将有助于表征环氧二碳三烯酸在脑卒中后小胶质细胞激活和小胶质细胞介导的损伤中的作用。候选人是一名麻醉师和神经强化医师，在缺血性脑损伤方面有很强的研究背景。候选人所在的机构提供了一个支持和合作的环境，非常适合培养新独立研究者的持续学术和科学发展。通过拟议的实验获得的额外专业知识将促进候选人作为独立研究人员的科学发展和成长。在这些研究中收集的证据将为未来R01的成功应用提供基础。

DESCRIPTION (provided by applicant): Stroke is the third leading cause of death and a major cause of long-term disability in the United States. Most clinical trials of acute stroke therapy have failed, underscoring the need to identify new therapeutic targets and develop effective therapies to reduce brain damage. Our broad goal in this proposal is to unravel the molecular pathways governing the detrimental effect of neuroinflammation and specifically microglia in stroke injury. Knowledge gained will help identify new drug targets for stroke therapy. The central hypothesis is that microglia are activated during ischemia and contribute to the development of injury. Two aspects of this microglia-mediated injury are explored, the depletion of epoxyeicosatrienoic acid (EET) during ischemia, which increases neuronal death, as well as the inactivation of EET after ischemia, which increases microglial activation and further exacerbates injury. In Specific Aim 1, we will determine whether microglia deplete EET through CD36-mediated uptake and whether EET deficiency contributes to neuronal death after ischemia. In Aim 2, we will determine whether depletion of EET by microglia contributes to stroke injury in vivo. In Aim 3, we will test whether blocking EET inactivation in microglia reduces microglial activation and microglia-mediated neuronal death. Finally, in Aim 4, we will investigate whether inhibition of EET-inactivating soluble epoxide hydrolase in microglia blocks microglial activation after stroke in vivo and reduces stroke injury. The overarching goals are to develop and characterize new experimental approaches to the clinical problem of stroke, specifically to understand the contribution of microglia to stroke pathology as well as use the increasing understanding of microglia/neuronal interplay and microglia-mediated injury to define new therapeutic targets and approaches for acute stroke. The experiments will help characterize the role of epoxyeicosatrienoic acid in microglia activation and microglia-mediated injury after stroke. The candidate is an anesthesiologist and neurointensivist with a strong research background studying ischemic brain injury. The candidate's institution provides a supportive and collaborative environment that is ideally suited to fostering the continued academic and scientific growth of a newly independent investigator. The additional expertise acquired through the proposed experiments will foster the candidate's scientific development and growth as an independent researcher. Evidence gathered in these studies will provide the base for a successful future R01 application.